Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.

Date publication

avril 2021

Journal

Lung cancer (Amsterdam, Netherlands)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier

Tous les auteurs :
Debieuvre D, Juergens RA, Asselain B, Audigier-Valette C, Auliac JB, Barlesi F, Benoit N, Bombaron P, Butts CA, Dixmier A, Gröschel A, Gutz S, Labbé C, Moro-Sibilot D, Pérol M, Raspaud C, Schumann C, Juarez-Garcia A, Lakhdari K, Pettersson F, Penrod JR, Reynaud D, Waldenberger D, Allan V, Sebastian M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33980420

Résumé

Immune checkpoint inhibitors have become the standard of care for metastatic non-small-cell lung cancer (NSCLC) progressing during or after platinum-based chemotherapy. Real-world clinical practice tends to represent more diverse patient characteristics than randomized clinical trials. We sought to evaluate overall survival (OS) outcomes in the total study population and in key subsets of patients who received nivolumab for previously treated advanced NSCLC in real-world settings in France, Germany, or Canada.

Mots clés

Nivolumab, Non–small-cell lung cancer, Observational study, Overall survival, Real-world data

Référence

Lung Cancer. 2021 Apr 30;: